BGM-2121 / BioGate Precision Medicine - LARVOL DELTA

BGM-2121, an anti-PTHrP monoclonal antibody, in advanced and metastatic solid tumors: A Phase 1, dose-escalation trial (ESMO 2026) - No abstract available

Metastases • P1 data • Oncology • Solid Tumor

PTHrP-associated gene programs in cancer cachexia and hypercalcemia and therapeutic targeting with anti-PTHrP antibody. (ASCO 2026) - "These findings define PTHrP-associated gene programs linked to cancer cachexia and hypercalcemia and demonstrate the therapeutic potential of PTHrP blockade. The PTHrP-targeting antibody BGM-2121 suppresses tumor growth and alleviates systemic complications in preclinical models, supporting PTHrP as a promising target for cancers with aggressive progression and metabolic dysregulation."

Cachexia • Colorectal Cancer • Endocrine Disorders • Metabolic Disorders • Oncology • Pancreatic Cancer • Solid Tumor • ACKR3 • KRAS • MMP14 • MMP2 • PTHLH • TGFB1

A phase 1 first-in-human study of BGM-2121 in patients with advanced solid tumors. (ASCO 2026) - P1 | "Dose modifications are determined by the Safety Review Committee. Treatment continues until disease progression, unacceptable toxicity, or loss of clinical benefit."

Clinical • First-in-human • Metastases • P1 data • Cachexia • Endocrine Disorders • Head and Neck Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

A Study of BGM-2121 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=35 | Recruiting | Sponsor: BioGate Precision Medicine Corp. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

A potent therapeutic antibody BGM-2121 targeting parathyroid hormone-related peptide (PTHrP) for pancreatic cancer (AACR 2025) - "In conclusion, this potent PTHrP-targeting antibody shows considerable promise as a therapeutic agent for cancers with PTHrP overexpression (e.g., pancreatic and lung cancers), humoral hypercalcemia of malignancy, and PTHrP-mediated cancer cachexia. We are currently preparing to submit an Investigational New Drug (IND) application to the TFDA and plan to initiate clinical trials to evaluate its potential as a novel biologic treatment for hard-to-treat metastatic cancers in Taiwan."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Oral Cancer • Pancreatic Cancer • Solid Tumor • KRAS • PTHLH

A Study of BGM-2121 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=35 | Not yet recruiting | Sponsor: BioGate Precision Medicine Corp.

First-in-human • New P1 trial • Solid Tumor